Table 1.
Demographic and laboratory characteristics of enrolled subjects
| Characteristic | Total patients (n=1,280) |
|---|---|
| Age (years) mean ±SD | 52.62±7.974 |
| Sex, n (%) Male; female |
1,100 (85.9%); 180 (14.1%) |
| Pre-treatment status, n (%) Naïve; experienced |
940 (73.4%); 340 (26.6%) |
| Fibrosis score by Fibroscan, n (%) F1;F2;F3; F4 |
90 (7%); 430 (33.6%); 290 (22.7%); 470 (36.7%) |
| Liver status (Child–Pugh score), n (%) Non-cirrhotic; A; B |
520 (40.6%); 370 (28.9); 390 (30.5%) |
| Pre-treatment prothrombin time (seconds), n (%) Normal; <4 seconds; >4 seconds |
570 (44.5%); 340 (26.6%); 370 (28.9%) |
| Pre-treatment ALT level, n (%) Normal; raised |
350 (27.3%); 930 (72.7%) |
| Pre-treatment serum bilirubin level, n (%) Normal; raised |
690 (53.9%); 590 (46.1%) |
| Pre-treatment serum albumin level (g/dL), mean ± SD | 3.662±0.5 |
| Pre-treatment serum bilirubin level (mg/dL), mean ± SD | 1.329±0.6 |